en Neurology Neurology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> Medication satisfaction is a patient-reported outcome which could show medication adherence. The aim of this study was to determine Iranian MS patients&rsquo; satisfaction with Disease Modifying Therapies (DMTs).</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Methods:</span></i></b> A standardized questionnaire was developed using Treatment Satisfaction Questionnaire for Medication (TSQM). The online link was released on IMSS (Iranian Multiple Sclerosis Society) social media channel, accessible to 4272 MS patients totally.<span style="font-size:10.0pt"></span></span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Results:</span></i></b> Three hundred and ninety-four patients participated in our survey with 324 females, 70 males and an F/M ratio of 4.6:1. The most frequent DMTs used were interferon-beta (IFN&beta;) followed by rituximab. The mean effectiveness and global satisfaction scores were significantly higher for injectable DMTs, while the convenience score was significantly higher for oral DMTs. Mean effectiveness and side-effect scores were significantly higher in the Tysabri group and convenience score was significantly higher in the fingolimod group while global satisfaction was higher in the IFN&beta; group.<b><i><span style="color:blue"></span></i></b></span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> The global satisfaction and effectiveness were significantly higher with injectable DMTs while the convenience score was significantly higher with oral DMTs.</span></span></span> Multiple sclerosis, satisfaction, medication. 89 93 http://caspjim.com/browse.php?a_code=A-10-2449-1&slc_lang=en&sid=1 Negar Molazadeh negar.molazadeh@gmail.com 100319475328460040839 100319475328460040839 No Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Mohammad ali Sahraian msahrai@tums.ac.ir 100319475328460040840 100319475328460040840 No Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Mahsa Ghajarzadeh m.ghajarzadeh@gmail.com 100319475328460040841 100319475328460040841 Yes Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran